Literature DB >> 8019629

The association of Chlamydia pneumoniae infection and reactive airway disease in children.

U Emre1, P M Roblin, M Gelling, W Dumornay, M Rao, M R Hammerschlag, J Schachter.   

Abstract

OBJECTIVE: To determine the possible association of Chlamydia pneumoniae infection and reactive airway disease in children.
DESIGN: Prospective observational study.
SETTING: Pediatric emergency department in Children's Medical Center of Brooklyn (NY), Kings County Hospital Center. PARTICIPANTS: One hundred eighteen children with acute episodes of wheezing and 41 age- and sex-matched healthy controls, aged 5 to 16 years.
INTERVENTIONS: Children with cultures positive for C pneumoniae were treated with antibiotics. MEASUREMENTS/MAIN
RESULTS: Cultures for C pneumoniae and serum samples for antibody testing were obtained from subjects and healthy controls. We isolated C pneumoniae from 13 (11%) children with wheezing and from two (4.9%) controls. Seven (58.3%) of 12 children with positive cultures had no detectable antibody to C pneumoniae and only three (25%) children had serologic evidence of acute infection. Six children had positive cultures on multiple occasions, ranging from 1 to 5 months. The children with wheezing were treated with erythromycin or clarithromycin, a new macrolide antibiotic approved for use in adults; all eventually had a negative culture. Nine (75%) of these children demonstrated clinical and laboratory improvement of the reactive airway disease after the eradication of chlamydial infection.
CONCLUSIONS: Infection with C pneumoniae can trigger acute episodes of wheezing in children with asthma. Treatment of C pneumoniae infection may improve the course of reactive airway disease in these patients.

Entities:  

Mesh:

Year:  1994        PMID: 8019629     DOI: 10.1001/archpedi.1994.02170070065013

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  49 in total

1.  Serological cross-reactions between Bartonella and Chlamydia species: implications for diagnosis.

Authors:  M Maurin; F Eb; J Etienne; D Raoult
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  The Role of Chlamydia in Upper Respiratory Tract Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.725

3.  Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals.

Authors:  A Schumacher; A B Lerkerød; I Seljeflot; L Sommervoll; I Holme; J E Otterstad; H Arnesen
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

4.  Current knowledge of Chlamydia pneumoniae and atherosclerosis.

Authors:  M R Hammerschlag
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

Review 5.  Pathogenesis of lower respiratory tract infections due to Chlamydia, Mycoplasma, Legionella and viruses.

Authors:  P Andersen
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

6.  Persistence of community-acquired respiratory distress syndrome toxin-producing Mycoplasma pneumoniae in refractory asthma.

Authors:  Jay Peters; Harjinder Singh; Edward G Brooks; Joseph Diaz; Thirumalai R Kannan; Jacqueline J Coalson; Janet G Baseman; Marianna Cagle; Joel B Baseman
Journal:  Chest       Date:  2011-05-26       Impact factor: 9.410

7.  Effect of hydrocortisone succinate on growth of Chlamydia pneumoniae in vitro.

Authors:  N Tsumura; U Emre; P Roblin; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

8.  In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.

Authors:  N Miyashita; Y Niki; T Kishimoto; M Nakajima; T Matsushima
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

9.  Atypical bacteria and macrolides in asthma.

Authors:  Paraskevi Xepapadaki; Ioanna Koutsoumpari; Vasiliki Papaevagelou; Christina Karagianni; Nikolaos G Papadopoulos
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

10.  beta2-agonists promote host defense against bacterial infection in primary human bronchial epithelial cells.

Authors:  Claire A Gross; Russell P Bowler; Rebecca M Green; Andrew R Weinberger; Christina Schnell; Hong Wei Chu
Journal:  BMC Pulm Med       Date:  2010-05-14       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.